Persistent Link:
http://hdl.handle.net/10150/614272
Title:
Effects of Exenatide Twice Daily and Once Weekly on Weight Loss
Author:
Patel, Rajal; Skuba, Katrina; Wild, Michelle; Slack, Marion
Affiliation:
College of Pharmacy, The University of Arizona
Issue Date:
2013
Rights:
Copyright © is held by the author.
Collection Information:
This item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Associate Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu.
Publisher:
The University of Arizona.
Abstract:
Specific Aims: To determine the effectiveness of exenatide twice daily (ExBID) versus exentatide once weekly (ExQW) on weight loss in type II diabetes. Methods: This study was a meta-analysis. The studies used came from the PubMed database and Cochrane Reviews. To be included in the meta-analysis, studies must have been randomized controlled trials comparing ExBID to ExQW or drug to placebo. The studies that reported weight loss and/or HbA1C were included. Studies that included participants <18 years of age or compared only one dose of exenatide with other anti-diabetic medication without comparing to placebo were excluded. There were 13 studies that met the inclusion criteria and were included in the meta-analysis. The primary outcome was weight loss, and the secondary outcome was HbA1C levels. Meta-analysis was used to synthesize data. Main Results: The difference between ExQW and ExBID on weight loss was not statistically significant (standardized mean difference (SMD) = -0.71, CI -0.84 to -0.58 in ExQW vs SMD = 0.82, CI -1.02 to -0.62 in ExBID; p =0.36). The effect of ExQW on A1C was significantly larger than ExBID (SMD = -1.69 vs -1.07 respectively; p < 0.01). The variability was very high in the ExBID group (69% - 81%) compared to ExQW group (0%). Kendall’s tau was significant (p= 0.01) indicating that there may be publication bias. Conclusion: There is no difference in effect of weight loss between ExQW and ExBID group. Both dosages significantly improve A1C; however, ExBID has larger impact on A1C compared to ExBID.
Description:
Class of 2013 Abstract
Keywords:
diabetes; Weight Loss; exenatide twice daily (ExBID); exentatide once weekly (ExQW)
Advisor:
Slack, Marion

Full metadata record

DC FieldValue Language
dc.contributor.advisorSlack, Marionen
dc.contributor.authorPatel, Rajalen
dc.contributor.authorSkuba, Katrinaen
dc.contributor.authorWild, Michelleen
dc.contributor.authorSlack, Marionen
dc.date.accessioned2016-06-22T22:36:11Z-
dc.date.available2016-06-22T22:36:11Z-
dc.date.issued2013-
dc.identifier.urihttp://hdl.handle.net/10150/614272-
dc.descriptionClass of 2013 Abstracten
dc.description.abstractSpecific Aims: To determine the effectiveness of exenatide twice daily (ExBID) versus exentatide once weekly (ExQW) on weight loss in type II diabetes. Methods: This study was a meta-analysis. The studies used came from the PubMed database and Cochrane Reviews. To be included in the meta-analysis, studies must have been randomized controlled trials comparing ExBID to ExQW or drug to placebo. The studies that reported weight loss and/or HbA1C were included. Studies that included participants <18 years of age or compared only one dose of exenatide with other anti-diabetic medication without comparing to placebo were excluded. There were 13 studies that met the inclusion criteria and were included in the meta-analysis. The primary outcome was weight loss, and the secondary outcome was HbA1C levels. Meta-analysis was used to synthesize data. Main Results: The difference between ExQW and ExBID on weight loss was not statistically significant (standardized mean difference (SMD) = -0.71, CI -0.84 to -0.58 in ExQW vs SMD = 0.82, CI -1.02 to -0.62 in ExBID; p =0.36). The effect of ExQW on A1C was significantly larger than ExBID (SMD = -1.69 vs -1.07 respectively; p < 0.01). The variability was very high in the ExBID group (69% - 81%) compared to ExQW group (0%). Kendall’s tau was significant (p= 0.01) indicating that there may be publication bias. Conclusion: There is no difference in effect of weight loss between ExQW and ExBID group. Both dosages significantly improve A1C; however, ExBID has larger impact on A1C compared to ExBID.en
dc.language.isoen_USen
dc.publisherThe University of Arizona.en
dc.rightsCopyright © is held by the author.en
dc.subjectdiabetesen
dc.subjectWeight Lossen
dc.subjectexenatide twice daily (ExBID)en
dc.subjectexentatide once weekly (ExQW)en
dc.titleEffects of Exenatide Twice Daily and Once Weekly on Weight Lossen_US
dc.typetexten
dc.typeElectronic Reporten
dc.contributor.departmentCollege of Pharmacy, The University of Arizonaen
dc.description.collectioninformationThis item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Associate Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu.en
All Items in UA Campus Repository are protected by copyright, with all rights reserved, unless otherwise indicated.